Shares of H. Lundbeck A/S- (NASDAQ:HLUYY) have earned a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

Zacks has also given H. Lundbeck A/S- an industry rank of 56 out of 265 based on the ratings given to its competitors.

Several research firms recently issued reports on HLUYY. Zacks Investment Research upgraded H. Lundbeck A/S- from a “hold” rating to a “strong-buy” rating and set a $69.00 price target on the stock in a research report on Friday, August 11th. Deutsche Bank AG lowered H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research report on Friday, July 28th.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at

H. Lundbeck A/S- (NASDAQ:HLUYY) traded up 1.80% during trading on Friday, hitting $56.85. The company had a trading volume of 10,609 shares. H. Lundbeck A/S- has a 1-year low of $31.00 and a 1-year high of $66.67. The stock has a market capitalization of $11.22 billion and a price-to-earnings ratio of 35.09. The company’s 50 day moving average price is $61.01 and its 200-day moving average price is $53.14.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with's FREE daily email newsletter.